Drugs like Ozempic may lower cancer risk if you have diabetes: study – National

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Drugs like Ozempic may lower ******* risk if you have diabetes: study – National

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in ******* prevention.

Now, a study of 170,000 patient records suggests there’s a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can’t prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson ******* Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

Story continues below advertisement

This is the hidden content, please

• Sign In
• or
• Sign Up

/applications/core/interface/js/spacer.png">

1:54
GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer’s risk for those with diabetes

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

Trending Now

• This is the hidden content, please

  • Sign In
  • or
  • Sign Up

  /applications/core/interface/js/spacer.png">

  Trump hits Springsteen with a golf ball in fake video as feud escalates

• This is the hidden content, please

  • Sign In
  • or
  • Sign Up

  /applications/core/interface/js/spacer.png">

  You did it, baby: New grad dad chased by cops after bringing infant son onstage

This is the hidden content, please

• Sign In
• or
• Sign Up

/applications/core/interface/js/spacer.png">

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don’t work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 U.S. health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related ******* and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related ******* in the GLP-1 group compared to 2,671 cases in the other group.

Story continues below advertisement

The effect was evident in women, but not statistically significant in men. The study couldn’t explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.

More on Health
More videos

&copy 2025 The ********* Press

This is the hidden content, please

• Sign In
• or
• Sign Up

#Drugs #Ozempic #******* #risk #diabetes #study #National

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up